Modality
Bispecific Ab
MOA
SOS1i
Target
GPRC5D
Pathway
JAK/STAT
RettADPKD
Development Pipeline
Preclinical
Sep 2020
→ Feb 2031
PreclinicalCurrent
NCT04691068
934 pts·ADPKD
2020-09→2031-02·Not yet recruiting
NCT07748141
1,751 pts·Rett
2022-06→2030-06·Completed
2,685 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-06-124.2y awayInterim· Rett
2031-02-124.9y awayInterim· ADPKD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Not yet…
Preclinical
Complet…
Catalysts
Interim
2030-06-12 · 4.2y away
Rett
Interim
2031-02-12 · 4.9y away
ADPKD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04691068 | Preclinical | ADPKD | Not yet recr... | 934 | UPCR |
| NCT07748141 | Preclinical | Rett | Completed | 1751 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |